Xe-Derma(®) is a new biological acellular temporary wound cover derived from pig dermis in the form of a mesh of collagen and elastic fibers. It is recommended for use in similar indications as classical pig xenografts. A data collection of 2 burns centres in the treatment of burns with Xe-Derma(®) was obtained from the medical records of 101 patients admitted from January 1, 2010 to December 31, 2011. The primary objectives of the study were to assess efficacy and safety when using Xe-Derma(®) in burn treatment, and to analyse the course of healing. The secondary objectives were to define the suitable spectrum of indications of Xe-Derma(®) in terms of burn depth, and to evaluate subsequent scarring using the Vancouver Scar Scale. No undesirable systemic effects or adverse device events were observed. The use of Xe-Derma(®) was not associated with a higher risk of burn wound infection. On the other hand, the infection was the most common cause of Xe-Derma(®) dissolution. The majority of patients (81.4%) had no signs of Xe-Derma(®) dissolution. The mean healing time in the group of patiens under review was close to 12 days and mean hospitalization time was almost 14 days. Using Xe-Derma(®) proved to be effective as a temporary covering for partial-thickness burns with the capacity of spontaneous healing. It proved to be a well-tolerated wound coverage with minimal complications and low level of pain during dressing changes. Xe-Derma(®) firmly adhered to the wound bed. There was a lower frequency of wound dressing changes and only a minimal rate of wound infection.

Le Xe-Derma® est un nouveau pansement acellulaire biologique provisoire à base de derme porcin, se présentant sous la forme d’un filet de fibres de collagène et d’élastine. Son utilisation est recommandée dans les indications similaires aux xenogreffes porcines classiques. Nous avons recueilli et analysé les données de 101 patients, dont les brûlures ont été traitées par Xe- Derma® dans 2 centres de grands brûlés entre le 1er janvier 2010 et le 31 décembre 2011. L’objectif principal de cette étude consistait à évaluer l’efficacité et la sécurité de l’utilisation du Xe-Derma® pour le traitement des brûlures et d’analyser le processus de guérison. Les objectifs secondaires étaient de déterminer un spectre d’indications pour l’utilisation du Xe-Derma® selon la gravité de la brûlure et d’évaluer le processus de cicatrisation consécutif à l’aide de la VSS (Vancouver Scar Scale, échelle cicatricielle de Vancouver). Aucun effet systémique défavorable ou effet local indésirable n’a été observé. L’utilisation du Xe-Derma® n’a pas été associée à un risque plus élevé d’apparition d’infections de la plaie. En revanche, les infections ont représenté la cause la plus fréquente de dissolution du Xe-Derma®. La majorité des patients (81,4%) n’ont toutefois manifesté aucun signe de dissolution du Xe-Derma®. Quelle que soit la gravité de la brûlure, le durée moyenne de guérison était proche de 12 jours et la durée moyenne d’hospitalisation était de presque 14 jours. L’utilisation du Xe-Derma® s’est avérée efficace en tant que pansement provisoire sur les brûlures de second degré, présentant un potentiel de guérison spontanée. Le Xe-Derma® est un pansement bien toléré, causant peu de complications et réduisant la douleur lors des changements de pansement. Il adhère très bien au fond de la plaie. La faible fréquence de changement de pansement a permis de limiter les infections des brûlures.

Burns Centre University Hospital Ostrava Ostrava Poruba Czech Republic

Dept of Burns Medicine Teaching Hospital Královské Vinohrady Šrobárova Prague Czech Republic

Division of Plastic Reconstructive Surgery and Burns Unit Dept of Surgery Charles University Prague Medical Faculty and Teaching Hospital in Hradec Králové Sokolská Hradec Králové Czech Republic ; Dept of Military Surgery Faculty of Military Health Sciences University of Defence Trebešská Hradec Králové Czech Republic

Zobrazit více v PubMed

Pospisilova A. Treatment of leg ulcers with XeDerma. Dermatologie pro praxi. 2009;3:191–3.

Zajicek R, Broz L, Klein L, et al. Xe-Derma: Nový biologický kryt pro lécbu akutních a chronických ran. Hojení ran. 2008;2:18–27.

Zajicek R, Matoušková E, Broz L, et al. New biological temporary skin cover Xe-Derma® in the treatment of superficial scald burns in children. Burns. 2011;37:333–7. PubMed

Königová R, Bláha J. Komplexní lécba popáleninového traumatu. Karolinum. 2010

Masellis M, Gunn SWA, editors. Dordrecht. Kluwer Academic Publishers; 1995. Clinical experience with skin xenografts in burned patients; pp. 337–45.

Vardaxis NJ, Brans TA, Boon ME, et al. Confocal laser scanning microscopy of porcine skin: Implications for human wound healing studies. Journal of Anatomy. 1997;190:601–11. PubMed PMC

Armour AD, Fish JS, Woodhouse KA, et al. A comparison of human and porcine acellularized dermis: Interactions with human fibroblasts in vitro. Plastic and reconstructive surgery. 2006;117:845–56. PubMed

Chiu T, Burd A. Xenograft dressing in the treatment of burns. Clinics in dermatology. 2005;23:419–23. PubMed

Pruitt BA, Levine NS. Characteristics and uses of biologic dressings and skin substitutes. Archives of surgery. 1984;119:312–22. PubMed

Takeuchi Y, Fishman J. Long life with or without PERV. Xenotransplantation. 2010;17:429–30. PubMed

Fishman JA, Scobie L, Tajeuchi Y. Xenotransplantation-associated infectious risk: A WHO consultation. Xenotransplantation. 2012;19:72–81. PubMed PMC

Di Nicuolo G, D´Alessandro A, Andria B, et al. Long-term absence of porcine endogenous retrovirus infection in chronically immunosuppressed patients after treatment with the porcine cellbased Academic Medical Center bioartificial liver. Xenotransplantation. 2010;17:431–9. PubMed

Irgang M, Sauer I M, Karlas A, et al. Porcine endogenous retroviruses: No infection in patients treated with a bioreactor based on porcine liver calls. Journal of clinical virology. 2003;28:141–54. PubMed

Valdez-Gonzalez R, Dorantes L M, Bracho-Blanchet E, et al. No evidence of porcine endogenous retrovirus in patients with type 1 diabetes after long-term porcine islet xenotransplantation. Journal of medical virology. 2010;82:331–4. PubMed

Klosova H, Nemeckova Crkvenjas Z, Petras L, et al. The use of acellular biological xenografts in local treatment of Lyell’s syndrome. Rozhledy v chirurgii. 2014;93:76–81. PubMed